| Acute myeloid leukemia with recurrent genetic abnormalities |
| AML with t(8;21)(q22;q22); (RUNX1;RUNX1T1) |
| AML with inv(16)(p13.1q22) or t((16;16)(p13.1;q22); (CBFB-MYH11) |
| APL with t(15;17)(q22;q12); (PML-RARA) |
| AML with t(9;11)(p22;q23); (MLLT3-MLL) |
| AML with t(6;9)(p23;q34); (DEK-NUP214) |
| AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); (RPN1-EVI1) |
| AML (megakaryoblastic) with t(1;22)(p13;q13); (RBM15-MKL1) |
| Provisional entity: AML with mutated NPM1 |
| Provisional entity: AML with mutated CEBPA |
| Acute myeloid leukemia with myelodysplasia-related changes |
| Therapy-related myeloid neoplasms |
| Acute myeloid leukemia, not otherwise specified |
| Similar to FAB subgroups |
